Cargando…
Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier España, S.L.U.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155831/ https://www.ncbi.nlm.nih.gov/pubmed/37207077 http://dx.doi.org/10.1016/j.medcle.2023.04.007 |
| _version_ | 1785036410778025984 |
|---|---|
| author | Fernández-Prada, María Pérez-Martín, Jaime Jesús Cienfuegos-González, Paula |
| author_facet | Fernández-Prada, María Pérez-Martín, Jaime Jesús Cienfuegos-González, Paula |
| author_sort | Fernández-Prada, María |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10155831 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier España, S.L.U. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101558312023-05-04 Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients Fernández-Prada, María Pérez-Martín, Jaime Jesús Cienfuegos-González, Paula Med Clin (Engl Ed) Scientific Letter Elsevier España, S.L.U. 2023-05-26 2023-05-03 /pmc/articles/PMC10155831/ /pubmed/37207077 http://dx.doi.org/10.1016/j.medcle.2023.04.007 Text en © 2023 Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Scientific Letter Fernández-Prada, María Pérez-Martín, Jaime Jesús Cienfuegos-González, Paula Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients |
| title | Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients |
| title_full | Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients |
| title_fullStr | Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients |
| title_full_unstemmed | Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients |
| title_short | Safety and immunogenicity of cilgavimab-tixagevimab for COVID-19 pre-exposure prophylaxis in immunocompromised patients |
| title_sort | safety and immunogenicity of cilgavimab-tixagevimab for covid-19 pre-exposure prophylaxis in immunocompromised patients |
| topic | Scientific Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155831/ https://www.ncbi.nlm.nih.gov/pubmed/37207077 http://dx.doi.org/10.1016/j.medcle.2023.04.007 |
| work_keys_str_mv | AT fernandezpradamaria safetyandimmunogenicityofcilgavimabtixagevimabforcovid19preexposureprophylaxisinimmunocompromisedpatients AT perezmartinjaimejesus safetyandimmunogenicityofcilgavimabtixagevimabforcovid19preexposureprophylaxisinimmunocompromisedpatients AT cienfuegosgonzalezpaula safetyandimmunogenicityofcilgavimabtixagevimabforcovid19preexposureprophylaxisinimmunocompromisedpatients |